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Abstract The yeast transcription factors Pdrl and Pdr3 control 
pleiotropic drug resistance (PDR) development, since they 
regulate expression of ATP-binding cassette (ABC) drug efflux 
pumps through binding to cw-acting sites known as PDREs 
(PDR responsive elements). In this report, we show by Northern 
blotting, gel shift mobility assays and DNase I footprinting that 
transcription of the ABC genes PDR10 and PDR15 is also 
controlled by Pdrl and Pdr3. In addition, in vitro band shift 
assays demonstrate that a GST-Pdrl fusion protein can bind to 
the PDREs of PDR10 and PDR15. DNase I footprinting 
allowed the identification of the precise PDRE binding motifs, 
indicating the presence of a novel slightly degenerate PDRE 
motif in the PDR15 promoter. Finally, PDR10 and PDR15 
mRNA levels vary dramatically in abundance in isogenic yeast 
strains carrying either Apdrl, Apdr3 and Apdrl Apdr3 deletions 
or pdrl-3 and pdr3-2 gain-of-function mutations, demonstrating 
that both PDR10 and PDR15 are new members of the yeast 
PDR network. 
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1. Introduction 
Multiple or pleiotropic drug resistance (PDR) in the yeast 
Saccharomyces cerevisiae can be controlled by the function of 
Pdrl [1] and Pdr3 [2], both of which belong to the Zn2CyS6 
family of transcriptional regulators. Although recent data also 
indicate that two hexose transporters can be controlled by 
Pdrl/Pdr3 [3], most known target genes of the yeast PDR 
network comprise membrane transporters of the ATP binding 
cassette (ABC) protein superfamily [4,5]. For instance, mRNA 
levels of PDR5 [6], SNQ2 [7,8] and possibly YOR1 [9] are 
tightly regulated by Pdrl/Pdr3. Gain-of-function mutations 
such as pdrl-3 or pdr3-2 lead to pleiotropic drug resistance 
to a variety of different drugs due to overexpression of several 
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drug efflux pumps [8,10], By contrast, loss-of-function muta-
tions such as Apdrl and Apdr3 result in severe drug hyper-
sensitivity phenotypes [2]. 
Transcriptional regulation within the PDR network was 
previously shown to require a PDRE (PDR responsive ele-
ment) consensus motif, which is present in varying numbers 
in the promoters of PDR responsive genes [2,11-13]. Several 
functional cw-acting PDREs protected by Pdrl in vitro have 
been identified in the PDR5 promoter [12]. Likewise, binding 
sites for Pdr3 have been identified in the promoters of PDR5 
[11], SNQ2 [8], PDR3 [13] and most recently in the hexose 
transporter genes HXT9 and HXT11 [3]. Notably, a single 
nucleotide exchange in a PDRE motif of PDR5 completely 
impaired the interaction of both Pdrl and Pdr3 with the 
PDR5 promoter [12]. This observation implies that the se-
quence motif for Pdrl/Pdr3 binding is quite restrictive. Never-
theless, in addition to the perfect palindromic PDRE motif, 
5'-TCCGCGGA-3', two other sequence elements, both of 
which contain one base change, 5'-TCCGTGGA-3' and 5'-
TCCGCGCA-3', were identified as potential Pdr3 target sites 
in certain PDR genes [3,9,12]. This suggests that at least some 
sequence degeneration may be tolerated without abolishing 
Pdrl and/or Pdr3 binding. Another potential target gene for 
transcriptional control by Pdrl and Pdr3 was identified in the 
ABC transporter gene YOR1. Its overexpression confers in-
creased resistance to oligomycin [9] and organic anions [14]. 
The YOR1 promoter contains only one PDRE motif, 5'-
TCCGTGGA-3', but this PDRE has not been shown to 
bind either Pdrl or Pdr3. 
The yeast genome sequencing project revealed the existence 
of 31 genes encoding ABC proteins [5,15]. The well-described 
Pdr5 [16,17] and Snq2 [18] drug efflux pumps, both of which 
are controlled by Pdrl and Pdr3 [6-8], have several homo-
logues whose functions and (drug) substrates are currently 
unknown. For instance, two ABC protein genes, PDR10 
[19] and PDR15, are most closely related to PDR5 [19]. Phy-
logenetic analysis suggests that Pdr5, PdrlO and Pdrl5 form a 
small subfamily of ABC proteins with more than 65% primary 
sequence identity to each other [5,15]. Interestingly enough, 
PDR10 and PDR15 contain two potential PDREs in their 
promoters. PDR10 has two degenerate PDRE motifs, the first 
(5'-TCCGTGGA-3') at position -407 and the second (5'-
TCCACGGA-3') at position -338 from the putative transla-
tional start. Likewise, the PDR15 promoter has two PDRE 
motifs, a perfect element (5'-TCCGCGGA-3') at position 
-379 and a degenerate element (5'-TCCGCGGGA-3') at po-
sition —442 from the putative translational start site. In this 
report, we demonstrate that Pdrl/Pdr3-mediated regulation 
also includes the PDR10 and PDR15 genes. In addition, we 
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have identified a novel degenerate PDRE motif in the PDR15 
promoter. 
2. Materials and methods 
2.1. Media, yeast strains and culture conditions 
Rich medium (YPD) and synthetic medium (SD), supplemented 
with auxotrophic components, were prepared essentially as described 
elsewhere [20]. The 5. cerevisiae strains used in this study were YALF-
Al (MATa ura3-52 leu2-3,112 his3-ll,15 trpl-1 pdrl-3) and its iso-
genic PDR1 segregant YALF-I1. These strains were constructed by 
back-crossing strain DRI9-T8 [6] successively into strains VHM3 [21], 
CRY2 and CB002 (kindly provided by B. Fuller), all of which are 
isogenic to W303-1A [22]. Likewise, pdr3-2 and its isogenic wild type 
strain, YYMI4-A4 {MATa pdr3-2 ura3 leu2 his3 trpl ade2) and 
YYMI4-03 {MATa PDR3 ura3 leu2 his3 trpl ade2), were obtained 
by back-crossing apdr3-2 allele [10] into strain YALF-02, an isogenic 
PDR1 segregant of the above described strain YALF-A1, and then 
three times into CRY1 or CRY2. The strains, FY1679-28C {MATa 
ura3-52 leu2M his3A200 trplA63), FY1619-28C/pdrl: :TRP1, 
FY\(,19-2%Clpdr3::HIS3 and FYl679-2SCIpdrl ::TRP1 pdr3::HIS3 
have been described elsewhere [2]. All yeast strains were grown rou-
tinely at 30°C. 
2.2. Plasmid construction 
The plasmids used as templates for PCR were constructed as fol-
lows. A 2.1 kbp Psil fragment from cosmid 9926 (ATCC 57093) 
containing the PDR15 promoter was cloned into the Psil site of 
pRS314 to obtain plasmid pHWl. Next, an 836 bp Smal-EcoRV 
fragment of pHWl was cloned into the Smal site of YEp368 to obtain 
pHWZ15. A 4.07 kbp SaulA fragment isolated from pUOA502 [19] 
containing the PDR10 promoter was cloned into the BamHl site of 
pBluescript SK~ to obtain plasmid pAA05. Then, a 1.7 kbp Hindi 
fragment from pAA05 was cloned into the Smal site of YEp368 
yielding plasmid pYM51. 
2.3. RNA isolation, radiolabeling and Northern analysis 
Total yeast RNA was isolated using a published procedure [23], and 
separated through a 1% agarose gel following the glyoxal procedure 
described elsewhere [24]. RNA was transferred onto nylon membranes 
by capillary blotting and hybridization of membranes was carried out 
by standard methods using the Church buffer (1% BSA fraction V, 7% 
SDS, 0.5 M Na-phosphate buffer pH 6.8, 1 mM EDTA) for both 
hybridization and washing, except for the PDR10 probe, which was 
hybridized and washed using a buffer containing Denhardt's solution 
[24]. DNA restriction fragments to be used as probes were derived 
from PDR5 [16], STE6 [22], SNQ2 [18], PDR10 [19] and PDR15 (K. 
Kuchler et al., unpublished data) and radiolabeled with [a32P]dCTP 
using a Megaprime Labeling Kit (Amersham) under conditions rec-
ommended by the manufacturer. Autoradiographs of Northern blots 
were quantified by laser scanning densitometry using the Image Quant 
software. 
2.4. GST fusion protein purification 
GST-Pdr3 fusion protein was purified as described previously [8,13] 
using minor modifications. To construct a bacterial expression plas-
mid for a GST-Pdrl fusion protein, a PDR1 -specific PCR fragment 
was amplified from plasmid pSKPDRl using an ohgonucleotide from 
the N-terminal PDR1 region (5'-G CGT GGA TCC CCG ATG CGA 
GGC TTG-3') and the universal primer Pu, both containing a BamHl 
site, and inserted into the BamHl site of pGEX-2T [25]. Briefly, 400 
ml LB medium containing 100 ug/ml ampicillin was inoculated with a 
10 ml overnight Escherichia coli preculture carrying the GST-Pdrl or 
the GST-Pdr3 fusion plasmid. Fusion protein expression was induced 
at an A600 of 0.5 by adding IPTG to a final concentration of 0.15 
mM. After a 4 h incubation at 37°C, the cells were harvested and 
resuspended in 20 ml cold TpG (20 mM Tris-HCl pH 8.0, 100 mM 
NaCl, 1 mM EDTA, 1 mM DTT, 0.1 mM ZnCl2 or ZnS04 , 0.5% 
NP-40; and PMSF 1 mM). Cells were disrupted by sonication and the 
insoluble material was removed by centrifugation at 15000 rpm for 15 
min. After addition of 500 |xl 50% slurry of glutathione Sepharose 
beads to the clear supernatant, binding was allowed at 4°C overnight 
with gentle shaking. The beads were collected by a brief centrifugation 
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and washed twice with 10 ml TpG. Finally, the beads were resus-
pended in 250 ul TpG and the fusion protein was eluted by adding 
250 ul of fresh elution buffer (50 mM Tris-HCl pH 8.0, 15 mM 
reduced glutathione). The fusion protein was eluted from the beads 
twice at room temperature for 10 min each. Eluates were combined 
and stored at -20°C [8,13]. 
2.5. DNA probe synthesis 
PDR10 and PDR15 promoter-specific probes PDR10-AB and 
PDR15-AB were synthesized by PCR using a 5' labeled ohgonucleo-
tide A and an unlabeled ohgonucleotide B in order to label only the 
coding strand. To do this, 2-3 pmol of ohgonucleotide A was labeled 
with 5-10 uCi y-ATP and 10 units T4-polynucleotide kinase for 2 h at 
37°C. The same molar amount of unlabeled ohgonucleotide B was 
added to the mixture. The DNA was purified by phenol extraction 
and precipitated overnight at —20°C. After centrifugation (15000 rpm 
for 30 min at 4°C), the pellet was washed with 70% ethanol and dried 
under vacuum. The DNA was dissolved and the probe was synthe-
sized by PCR under optimized conditions (0.2 mM dNTP, 2.5 units 
Taq, 1.5 mM MgCl2). The amplified promoter probes PDR10-AB and 
PDR15-AB were purified by phenol extraction and precipitated in the 
presence of glycogen overnight at —20°C. The DNA probes were 
dissolved in H2O at a final concentration of 100 fmol/itl. The labeled 
oligonucleotides for probe synthesis were: PDR10-A (5'-CGC TGC 
ACC ATT CGC GC-3') and PDR15-A (5'-TGC CCT GGA AGG 
TGG CC-3'); the non-labeled oligonucleotides were PDR10-B (5'-
TTG GTA CTG ATG ACA GCA GG-3') and PDR15-B (5'-TCG 
CAC AGC AGT AGC AG-3'). Template DNA for PCR was derived 
from pYM51 {PDR10) and pHWZ15 {PDR15), respectively. 
2.6. Mobility shift assay 
Radiolabeled DNA fragments PDR10-AB and PDR15-AB harbor-
ing appropriate promoter regions of PDR10 and PDR15 were gener-
ated by PCR as described above. The purified fusion protein GST-
Pdrl was incubated for 30 min at 25°C with 5-20 fmol labeled probe 
in assay buffer (100 mM KC1, 20 mM Tris-HCl pH 8, 5 mM MgCl2, 
0.5 mM DTT, 0.5 mM CaCl2, 0.1 mM EDTA with 5% glycerol, 0.05 
(Xg/jxl sonicated and non-denatured salmon sperm DNA). After incu-
bation for another 20 min on ice, the mixture was loaded onto a 
native 4% polyacrylamide gel (acrylamide:bis-acrylamide 29.1:0.9 in 
0.5XTBE buffer). After the gel was prerun at 200 V for 30 min, 
samples were applied and electrophoresis was carried out in 
0.5XTBE buffer at 240 V. After electrophoresis, the gel was exposed 
to an autoradiography film at — 70°C using intensifying screens. 
2.7. DNase I footprinting 
Binding conditions for the DNase I treatment were identical to 
those used in the mobility shift assay, but glycerol was excluded 
from the buffer. After a preincubation for 30 min at 25°C, the DNase 
I digestion was performed with increasing activities of DNase I (0.5 
U, 1 U, 2 U; Boehringer Mannheim) and stopped after 1 min by 
phenol extraction. The DNA was precipitated in liquid N2 . After 
centrifugation, the pellet was washed once with 70% ethanol and 
resuspended twice in 100 ul H 2 0 with intermediate lyophilization 
and finally, after lyophilization, resuspended in formamide dye (95% 
formamide, 20 mM EDTA, 0.05% bromophenol blue, 0.05% xylene 
cyanol FF). After denaturation at 92°C for 5 min, half of the sam-
ples were loaded onto a denaturing gel (6%, acrylamide:bis-
acrylamide= 19:1 in 0.5XTBE buffer containing 50% urea) along 
with the samples from a Maxam-Gilbert reaction performed on 
the same probes. Electrophoresis was carried out at 20 W. The gel 
was dried and exposed to an X-ray film with intensifying screen at 
-70°C. 
2.8. Maxam-Gilbert sequencing reaction (A+G) 
100 fmol 5'-end-labeled DNA fragments was dried under vacuum 
in the presence of 1 ug of salmon sperm carrier DNA. The DNA 
pellet was resuspended in 2 ul 2% formic acid and incubated for 10 
min at 37°C. After drying, the pellet was dissolved in 100 ul 1 M 
piperidine and incubated for 30 min at 90°C. Piperidine was removed 
from the samples by lyophilization and the pellet was washed twice in 
distilled H 2 0 with intermediate lyophilization to remove residual pi-
peridine. Finally, the pellet was resuspended in formamide dye at a 
concentration of 2 fmol/ul and loaded onto the DNase I footprint gel. 
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3. Results 
3.1. Pdrl binds to two distinct sites in the promoters of PDR10 
and PDR15 in vitro 
The completion of the sequencing project revealed the ex-
istence of 31 distinct ABC protein genes in yeast [5,15]. For 
instance, expression of PDR5 and SNQ2, both of which en-
code ABC drug efflux pumps of broad substrate specificity, is 
controlled by the ZnaCyse-type transcriptional regulators 
Pdrl and Pdr3. This regulation requires so-called PDREs 
present in the promoters of PDR responsive genes, several 
of which have been identified so far (Fig. 1). The PDR5 
gene has two additional homologues, PDR10 and PDR15, 
both of which are some 65% identical to Pdr5 over their entire 
length (data not shown). Interestingly, each promoter of these 
ABC genes contains two different putative PDREs in the 5'-
untranslated region. Since only one PDRE is necessary and 
sufficient for conferring Pdrl/Pdr3-mediated regulation on 
genes, we wanted to test whether recombinant Pdrl and 
Pdr3 can bind to the promoters of PDR10 and PDR15. To 
accomplish this, a GST-Pdrl fusion protein was expressed in 
E. coli. After its purification, the fusion protein was used in 
gel retardation assays. As shown in Fig. 2, recombinant GST-
Pdrl protein could indeed bind to the promoters of both 
PDR10 and PDR15 in vitro, because the mobility of the 
free DNA probes was retarded in the gel only in the presence 
of the GST-Pdrl protein but not in the control lanes. Increas-
ing the amount of GST-Pdrl led in each case (PDR10 and 
PDR15) to a supershift, suggesting that Pdrl binds to both 
sites of each promoter (Fig. 2). Similar results were obtained 
using a recombinant GST-Pdr3 fusion protein, which also 
bound twice to both promoters (data not shown). These re-
sults demonstrate that the PDR10 and PDR15 promoters con-
tain functional PDREs specifically recognized by recombinant 
GST-Pdrl and GST-Pdr3 in vitro. 
TCCGCGGA E52 TCCAJDGGA m TCCGCGGfiA 
I I TCCGT.GGA I 1 TCCGCGEA 
Fig. 1. Different PDREs are present in the promoters of Pdrl/Pdr3 
target genes. Boxes represent the PDRE motifs. Numbers below in-
dicate the position of the first PDRE nucleotide relative to the puta-




Fig. 2. GST-Pdrl can bind to both PDREs in the promoters of 
PDR10 and PDR15. In the gel retardation assay, the band of the 
free DNA probe (arrows) is partially shifted (circles) upon addition 
of recombinant Pdrl-GST fusion protein. Increasing the amount of 
Pdrl-GST from about 0.1 nM (lane 1) to 16 nM (lane 4) leads to a 
supershift (boxes). In the control (lane 0) no fusion protein was 
added. 
3.2. Identification of two Pdrl binding sites in the PDR15 
promoter 
To precisely identify the actual sequence elements recog-
nized by Pdrl in the PDR15 promoter, a DNase I footprint 
assay was performed using the specific DNA probe PDR15-
AB in the presence or absence of the GST-Pdrl protein. The 
results shown in Fig. 3 confirmed that the above suspected 
PDREs (Fig. 1) in the PDR15 promoter can indeed be pro-
tected by recombinant GST-Pdrl. The Maxam-Gilbert reac-
tion on the same DNA fragment (A+G) enabled the identi-
fication of the actual sequence of the Pdrl-protected sites. As 
shown in Fig. 3, the sequences protected by GST-Pdrl contain 
the consensus PDRE motif (5'-TCCGCGGA-3') and the de-
generate 5'-TCCGCGGGA-3' PDRE site. Similarly, footprint 
analysis on the PDR10 promoter also confirmed the two dif-
ferent potential PDRE motifs to be protected by GST-Pdrl in 
vitro (data not shown). 
3.3. mRNA levels of PDR10 and PDR15 fluctuate in pdrl and 
pdr3 mutants 
Transcription of the PDR5 gene is under the control of 
Pdrl/Pdr3, since PDR5 mRNA was found to be of higher 
abundance in pdrl-3 gain-of-function mutants [6]. To test if 
this is also the case for PDR10 and PDR15, we performed 
Northern analysis on total RNA isolated from isogenic PDR1 
and pdrl-3 strains as well as PDR3 and pdr3-2 gain-of-func-
tion mutants (Fig. 4). Quantification of the results by laser 
scanning densitometry indicated that the PDR10 mRNA was 
10-fold increased in a pdrl-3 mutant when compared to the 
isogenic PDR1 wild type strain (Fig. 4) However, PDR10 
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mRNA levels were almost unchanged in the pdr3-2 mutant. 
The mRNA for PDR15 was about 5-fold more abundant in 
pdrl-3 and at least 20-fold increased in pdr3'-2 when compared 
to each of the corresponding isogenic wild type strains WT-2 
and WT-3 (Fig. 4). Hybridization of the same Northern blot 
with PDR5- and STM-specific probes served as positive and 
negative controls for target genes of the yeast PDR network, 
respectively, and allowed the verification of equal RNA load-
ing in each lane. While PDR5 mRNA was massively induced 
in both pdrl-3 and pdr3-2 strains, STE6 mRNA levels re-
mained constant in all strains tested as described previously 
[8]. 
Previous studies indicated that both Pdrl and Pdr3 can 
recognize the PDRE consensus motif with the sequence 5'-
TCCGCGGA-3' [11-13]. Consistent with the observed upreg-
ulation of PDR10 and PDR15 in gain-of-function mutants, 
one would predict and expect reduced mRNA levels of the 
genes in question in yeast strains lacking Pdrl and/or Pdr3. 
Thus, we performed Northern analysis on total RNA isolated 
from a set of isogenic yeast strains harboring Apdrl, Apdr3 
and Apdrl Apdr3 deletion mutations. Although the amount of 
PDR10 mRNA was not affected in the Apdrl strain, it was 
severely affected in the Apdr3 and in the Apdrl Apdr3 double 
mutant. Surprisingly, we consistently found increased mRNA 
levels of PDR15 in a Apdrl strain when compared to the 
i r 
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Fig. 4. Northern blot analysis on RNA from isogenic Apdrl/Apdr3 
and pdrl-3 and pdr3-2 mutant strains. Total yeast RNA was iso-
lated from strains FY1679-28C (WT-1), FYl619-2SC/pdrl::TRPl 
(Apdrl), FYl679-28C/pdr3::HIS3 (Apdr3), FY1619-28Clpdrl::TRPl 
pdr3::HIS3 (Apdrl Apdr3), YALF-I1 (WT-2), YALF-A1 (pdrl-3), 
YYMI4-03 (WT-3) and YYMI4-A4 (pdr3-2). About 18 ug RNA 
were fractionated as described in Section 2. The radiolabeled DNA 
fragments used for hybridization were derived from PDR10 (nt +93 
to +1109; exposure time: 190 h), PDR15 (nt +13 to +721; exposure 
time: 120 h), PDR5 (nt +14 to +977; exposure time: 45 min) and 
STE6 (nt - 1 to +981; exposure time: 20 h on blot A, 70 h on blot 
B). 
corresponding isogenic wild type WT-1 (Fig. 4). By contrast, 
PDR15 transcription was almost completely obliterated in the 
Apdr3 and the Apdrl Apdr3 double mutant. Again, Pdr3 ap-
pears to have a more pronounced effect on the control of 
PDR15 than Pdrl. As expected, the levels of STE6 mRNA 
were completely unaffected in any of the strains tested, con-
firming equal RNA loading in each lane. 
Taken together, our results demonstrate that both PDR10 
and PDR15 are novel targets for regulation by the Pdrl and 
Pdr3 transcription factors. In addition, our results suggest a 
novel PDRE motif with the sequence 5'-TCCGCGGGA-3' in 
the PDR15 promoter to be recognized by the Pdrl/Pdr3 reg-
ulators. 
4. Discussion 
Fig. 3. DNase I footprint analysis identifies PDREs protected by a 
Pdrl-GST fusion protein in the PDR15 promoter. The 5'-labeled 
DNA fragment PDR15-AB was treated with DNase I with (+) or 
without (—) prior incubation with Pdrl-GST fusion protein. Sam-
ples from a Maxam-Gilbert reaction (A+G) on the same DNA frag-
ment were also loaded. Both sequences protected by Pdrl-GST con-
tain a PDRE motif (underlined). 
In this report we have shown that PDR10 and PDR15 are 
subject to transcriptional control by the yeast PDR network. 
Hence, the yeast PDR network now comprises all of the yeast 
Pdr5 subfamily members, as well as Snq2 [8], Yorl [9], Hxt9 
and Hxtl l [3]. Moreover, we show that the collection of 
PDREs mediating Pdrl/Pdr3 control also include the novel 
5'-TCCGCGGGA-3' element, in addition to the PDREs 
known so far (5'-TCCGCGGA-3\ 5'-TCCGTGGA-3', 5'-
TCCGCGCA-3', and 5'-TCCACGGA-3') found in the pro-
moters of PDR responsive genes (Fig. 1). These results suggest 
that Pdrl and Pdr3 tolerate at least some sequence degener-
ation in the PDRE without abolishing their binding to target 
genes. The functional significance of various PDRE motifs 
present in different numbers and relative position to the trans-
lational start site is not entirely clear. However, we propose 
that different combinations of PDREs could contribute to a 
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differential control of target genes by Pdrl, Pdr3 or both 
transcription factors under certain physiological conditions. 
For example, the 5'-TCCACGGA-3' PDRE has been shown 
to bind both Pdrl and Pdr3 in the PDR5 promoter [12], 
whereas no binding of Pdr3 to the same element was observed 
in the promoter of HXT11 [3]. In contrast, our results from 
gel retardation assays and DNase I footprints (Fig. 1, open 
boxes) on the PDR10 promoter indicate binding of both Pdrl 
(Fig. 2) and Pdr3 (data not shown) to the 5'-TCCACGGA-3' 
PDRE. 
Finally, one can argue that Pdrl and Pdr3 might have dif-
ferent affinities for different combinations of PDREs. One 
could speculate that different target genes can be differentially 
controlled by either Pdrl or Pdr3 depending on the combina-
tions of PDREs present in their promoters. This would pro-
vide a possible explanation for the drastic difference in the 
expression levels of PDR5, PDR10 and PDR15 in normal 
cells, all of which possess quite different PDREs. Indeed, evi-
dence from Northern blot analysis suggests that PDR5 is most 
highly abundant, while PDR10 and PDR15 are expressed at 
much lower levels. It will therefore be important in future 
studies to evaluate the binding affinities of authentic Pdrl 
and Pdr3 for the different PDRE combinations of individual 
PDR genes. 
Additional transcription factors such as Yapl [26], which is 
otherwise required for the general stress response [26,27], 
might also contribute to transcriptional control within the 
PDR network. For instance, induced expression of Snq2, 
which is also regulated by Pdrl and Pdr3 [8], in cells respond-
ing to various external stress conditions requires a functional 
YAP1 gene (Y. Mahe et al., in preparation). Furthermore, we 
have recently shown that a Yapl-mediated diazaborine resist-
ance phenotype requires the presence of functional Pdrl and 
Pdr3 [28], demonstrating a link between the general stress 
response pathway and the PDR network. Interestingly, the 
transcription factor Nggl, a dual function regulator required 
for glucose repression [29], is thought to directly inhibit Pdrl 
function in wild type cells [30], thereby also contributing to 
this process of specific gene regulation within the PDR net-
work. 
Surprisingly, our studies also revealed that a Apdrl deletion 
mutation not always leads to reduced expression of target 
genes. Our data clearly and consistently demonstrate that 
PDR15 mRNA is up-regulated several-fold in a Apdrl strain, 
but almost abolished in a Apdrl Apdr3 double deletion (Fig. 
4). While we consider the possibility of an increased PDR15 
mRNA stability unlikely, we speculate that this upregulation 
could be due to a lack of interaction with other yet unknown 
transcription factors, which together with Pdrl could nega-
tively control PDR15 in wild type cells. For instance, Pdr3 
might become more important for PDR15 control and exhibit 
higher affinities to the PDR15 promoter when Pdrl is absent, 
which is exactly what our results indicate. This is also consist-
ent with the 20-fold higher abundance of PDR15 mRNA in 
pdr3-2 gain-of-function mutants (Fig. 4). 
A similar discrepancy between the effects of ApdrllApdr3 
deletions and pdrl-3/pdr3-2 gain-of-function mutations is ob-
served in the regulation of PDR10. While the Apdrl strain 
shows only a slight decrease in PDR10 mRNA levels, it is 
highly up-regulated in the pdrl-3 mutant. By contrast, the 
Apdr3 deletion severely reduces PDR10 mRNA levels, whereas 
the pdr3-2 gain-of-function mutant seems to have hardly any 
effect at all. Taken together, we hypothesize that these results 
imply a functional cross-talk between Pdrl and Pdr3 and 
perhaps other yet unknown transcriptional regulators in the 
regulation of PDR10 and PDR15. While the physiological 
function of PdrlO and Pdrl5 remains obscure at the moment, 
it will certainly be interesting to determine whether or not 
PdrlO and Pdrl5, like Pdr5, represent functional ABC drug 
efflux pumps. 
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